Média

The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class product derived directly from this technology Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that…read more →

Onxeo Announces Its Financial Calendar for 2017

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced its financial calendar for 2017: March 7, 2017                                      Full-year 2016 consolidated accounts  April 26, 2017                                      General shareholders’ meeting (to be convened in Paris) April 27,…read more →

Onxeo Strengthens AsiDNA™ Patent Protection in Europe

Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence until 2027 Any product including this specific DNA sequence will be within the scope of this patent AsiDNA™’s intellectual property will now be protected by 8 complementary patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen:…read more →

Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the management of the company will hold one-on-one investor meetings at the Guggenheim Securities 4th Annual Boston Healthcare Conference, taking place Tuesday, December 13, 2016 at…read more →

Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 9th unanimous recommendation from the Data Safety Monitoring Board (DSMB), an independent European board of experts that monitors the safety of…read more →

Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced encouraging results from a series of preclinical studies evaluating Livatag® interest for pancreatic cancer. Livatag® (doxorubicine Transdrug™, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically…read more →

Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors

Combination with checkpoint inhibitors decreased tumor growth rate and prolonged survival in syngeneic HCC mouse model Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced promising results from preclinical studies evaluating the potential of its already…read more →

Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update

Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients randomized  €12.5m capital increase successfully completed Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today published its consolidated financials for the period ending September 30, 2016…read more →

Publication of Shareholder Letter

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced the publication of an Onxeo Shareholder Letter. This Shareholder Letter provides an update on Onxeo’s achievements in 2016 so far with a special focus on the newest addition to our pipeline, AsiDNATM. The Shareholder Letter is…read more →

Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that Company management is scheduled to present at the 15th Annual BIO Investor Forum, being held October 18-19, 2016 at the Westin St. Francis in San Francisco,…read more →

Onxeo Raises €12.5 Million through Capital Increase with US and European Investors

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the successful completion of a capital increase of 5,434,783 new ordinary shares for gross proceeds of €12.5 million. Guggenheim Securities, LLC and Oddo…read more →